Prognostic factors in male breast cancer: a population-based study

Leone, José Pablo; Zwenger, Ariel Osvaldo; Iturbe, Julian; Leone, Julieta; Leone, Bernardo Amadeo; Vallejo, Carlos; Bhargava, Rohit

doi:10.1007/s10549-016-3768-1

Cited by 44 publications

(53 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in subgroup analysis, the expression of TAZ/CTGF and YAP/CTGF conferred poorer overall survival in patients with G3 tumors, but not in those with G1-2 tumors. In the entire population ( N = 129), higher tumor grade seemed to be also associated with shorter survival, and this is consistent with an independent study that analyzed survival outcomes of ~3.000 MBC patients [51]. A plausible hypothesis is that TAZ/YAP activity may be also necessary for maintenance/amplification of the CSC compartment in MBC.…”

Section: Discussionsupporting

confidence: 83%

The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer

Benedetto¹,

Mottolese²,

Sperati³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Male breast cancer (MBC) is a rare disease and its biology is poorly understood. Deregulated Hippo pathway promotes oncogenic functions in female breast cancer. We herein investigated the expression of the Hippo transducers TAZ/YAP and their target CTGF in MBC. Tissue microarrays containing samples from 255 MBC patients were immunostained for TAZ, YAP and CTGF. One hundred and twenty-nine patients were considered eligible. The Pearson's Chi-squared test of independence was used to test the association between categorical variables. The correlation between TAZ, YAP and CTGF was assessed with the Pearson's correlation coefficient. The Kaplan-Meier method and the log-rank test were used for estimating and comparing survival curves. Cox proportional regression models were built to identify variables impacting overall survival. Statistical tests were two-sided. Tumors were considered to harbor active TAZ/YAP-driven gene transcription when they co-expressed TAZ, or YAP, and CTGF. Patients whose tumors had the TAZ/CTGF and YAP/CTGF phenotypes experienced shorter overall survival compared with their negative counterparts (log rank p = 0.036 for both). TAZ/CTGF and YAP/CTGF tumors were associated with decreased survival in patients with invasive ductal carcinomas, G3 tumors, hormone receptor-positive tumors, and tumors with elevated Ki-67. Multivariate analyses confirmed that the TAZ/CTGF and YAP/CTGF phenotypes are independent predictors of survival (HR 2.03, 95% CI: 1.06–3.90, p = 0.033; and HR 2.00, 95% CI: 1.04–3.84, p = 0.037 respectively). Comparable results were obtained when excluding uncommon histotypes (TAZ/CTGF: HR 2.34, 95% CI: 1.16–4.73, p = 0.018. YAP/CTGF: HR 2.36, 95% CI: 1.17–4.77, p = 0.017). Overall, the TAZ/YAP-driven oncogenic program may be active in MBC, conferring poorer survival.

show abstract

Section: Discussionsupporting

confidence: 83%

The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer

Benedetto¹,

Mottolese²,

Sperati³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Leone et al found that age at diagnosis, tumor grade, stage, surgery, radiotherapy, ER, and marital status have a clear impact on OS in MBC 12. Masci et al suggested that grade III and Ki-67>20% were associated with shorter OS 23.…”

Section: Discussionmentioning

confidence: 99%

“…The median diagnosis age of MBC is 68 years and it is 5–10 years later than FBC 6. While the mortality rate of MBC improved in the last 30 years,11 the overall 5-year and 10-year survival rates are 70.6% and 53.7%, respectively 12. Thus, MBC is a disease that cannot be ignored and requires extensive research.…”

Section: Introductionmentioning

confidence: 99%

Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016

Wang

Tian

et al. 2019

Journal of Investigative Medicine

View full text Add to dashboard Cite

This study aims to understand the clinical features, treatment, and prognosis of patients with male breast cancer (MBC) in Shanxi province of China from 2007 to 2016. Data for 77 patients with MBC were collected for analysis. Immunohistochemistry, pathological results, and other data such as demographic characteristics (age, marital status, smoking history, drinking history, and family history of cancer) as well as clinical data were investigated by retrieving information from the patients’ medical records. A total of 12,404 patients were diagnosed with breast cancer between 2007 and 2016, and 77 were patients with MBC among them. The median diagnosis age of patients with MBC was 62 years (range, 24–84 years). The most common complaint was a painless lump in the breast, accounting for 68.8% of the patients, and the main pathological type in MBC was infiltrating ductal carcinoma (66.2%). In terms of hormone receptors, 80.5% (62/77) of patients with MBC were estrogen receptor positive, 75.3% (58/77) of patients were progesterone receptor positive, and only 6.5% (5/77) of patients were HER2 overexpressing. The multivariant Cox proportional hazards regression analysis showed that M stage is an independent prognostic factor (p=0.018, HR=18.791, 95% CI 1.663 to 212.6). The epidemiological and clinical features of Chinese MBC are similar to that of other countries. As the Chinese public have limited knowledge of MBC, it is necessary to increase awareness among them about it. Further research with a large sample size is required for better understanding of the risks associated with MBC.

show abstract

“…Although tamoxifen is a beneficial treatment, it is not without clinical issues including side effects such as reduced libido and impotence (Arnould et al 2006), which may lead to a clinical or patient decision to stop treatment (Fentiman et al 2006). In addition, the prognostic indicators are not necessarily the same between male and female breast cancers, making it difficult to determine which patients truly require treatment (Abreu et al 2016, Leone et al 2016.…”

Section: Clinical Featuresmentioning

confidence: 99%

A review of estrogen receptor/androgen receptor genomics in male breast cancer

Severson¹,

Zwart²

2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

Male breast cancer is a rare disease, of which little is known. In contrast to female breast cancer, the very vast majority of all cases are positive for estrogen receptor alpha (ERα), implicating the function of this steroid hormone receptor in tumor development and progression. Consequently, adjuvant treatment of male breast cancer revolves around inhibition of ERα. In addition, the androgen receptor (AR) gradually receives more attention as a relevant novel target in breast cancer treatment. Importantly, the rationale of treatment decision making is strongly based on parallels with female breast cancer. Yet, prognostic indicators are not necessarily the same in breast cancer between both genders, complicating translatability of knowledge developed in female breast cancer toward male patients. Even though ERα and AR are expressed both in female and male disease, are the genomic functions of both steroid hormone receptors conserved between genders? Recent studies have reported on mutational and epigenetic similarities and differences between male and female breast cancer, further suggesting that some features are strongly conserved between the two diseases, whereas others are not. This review critically discusses the recent developments in the study of male breast cancer in relation to ERα and AR action and highlights the potential future studies to further elucidate the genomic regulation of this rare disease.

show abstract

Prognostic factors in male breast cancer: a population-based study

Cited by 44 publications

References 21 publications

The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer

The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer

Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016

A review of estrogen receptor/androgen receptor genomics in male breast cancer

Contact Info

Product

Resources

About